Voorbeelden van het gebruik van Fexeric in het Engels en hun vertalingen in het Nederlands
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
How is Fexeric used?
Fexeric 1 g carton only.
Why is Fexeric approved?
Other information about Fexeric.
Fexeric is available as 1 g tablets.
Effects of other medicinal products on Fexeric.
Effects of Fexeric on other medicinal products.
No data are available regarding overdose of Fexeric in humans.
What Fexeric looks like and contents of the pack?
are observed with Fexeric use.
Fexeric increases iron levels in your body.
It is unknown whether Fexeric has any effect on unborn babies.
Fexeric contains sunset yellow FCF(E110)
If you take too much Fexeric, tell your doctor of pharmacist.
Fexeric has no influence on your ability to drive
TSAT above safety thresholds are observed with Fexeric use.
Fexeric should not be taken at the same time as aluminium containing medicines.
However, there was no interaction when Fexeric and ciprofloxacin were taken 2 hours apart.
Fexeric film-coated tablets are peach-coloured,
None of the reported serious events in Study 204 were considered to be possibly related to Fexeric.
Fexeric is indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease CKD.
Table 2: Adverse reactions observed during clinical studies in which Fexeric was administered in CKD ND patients.
Fexeric should be temporarily discontinued if serum ferritin exceeds 800 ng/ml see section 4.4.
at least 2 hours before or after Fexeric.
Fexeric binds to the phosphorus from food in your digestive tract to prevent it from being absorbed into your blood.
Patients previously on other phosphate binders who are switched to Fexeric should start taking 3 to 6 g(3 to 6 tablets) per day.
aluminium-based compounds should be avoided while patients receive Fexeric.
The study showed that blood-phosphate levels fell on average by 0.7 mg/dl with Fexeric compared with 0.3 mg/dl with placebo.
were each reported in 0.2%(1/557) of CKD 5D patients who received Fexeric.
Fexeric did not alter the bioavailability of the following medicinal products when concomitantly administered: